Eledon Pharmaceuticals (ELDN) Shares Outstanding (Diluted Average) (2021 - 2026)

Eledon Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $112.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 45.77% year-over-year to $112.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.4 million (up 45.77% YoY), and the FY2025 full-year result was $81.8 million, up 68.58% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $112.4 million, up from $81.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $112.4 million in Q1 2026, with the low at $114508.0 in Q1 2024.
• Historically, Shares Outstanding (Diluted Average) has averaged $38.1 million across 5 years, with a median of $22.8 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) sank 99.52% — and 2025, when it jumped 67280.5%.
• Eledon Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $14.3 million in 2022, then slumped by 99.17% to $118268.0 in 2023, then jumped by 40945.58% to $48.5 million in 2024, then surged by 68.58% to $81.8 million in 2025, then soared by 37.38% to $112.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $112.4 million (Q1 2026), $81.8 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.